These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9343219)

  • 1. Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development.
    Cao H; Kanki P; Sankalé JL; Dieng-Sarr A; Mazzara GP; Kalams SA; Korber B; Mboup S; Walker BD
    J Virol; 1997 Nov; 71(11):8615-23. PubMed ID: 9343219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children.
    Goulder PJ; Brander C; Annamalai K; Mngqundaniso N; Govender U; Tang Y; He S; Hartman KE; O'Callaghan CA; Ogg GS; Altfeld MA; Rosenberg ES; Cao H; Kalams SA; Hammond M; Bunce M; Pelton SI; Burchett SA; McIntosh K; Coovadia HM; Walker BD
    J Virol; 2000 Jun; 74(12):5679-90. PubMed ID: 10823876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
    Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
    Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CTL epitope distribution patterns in the Gag and Nef proteins of HIV-1 from subtype A infected subjects in Kenya: use of multiple peptide sets increases the detectable breadth of the CTL response.
    Currier JR; Visawapoka U; Tovanabutra S; Mason CJ; Birx DL; McCutchan FE; Cox JH
    BMC Immunol; 2006 Apr; 7():8. PubMed ID: 16620386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of cross-clade CTL epitopes in HIV-1 clade A/E-infected individuals by using the clade B overlapping peptides.
    Watanabe K; Murakoshi H; Tamura Y; Koyanagi M; Chikata T; Gatanaga H; Oka S; Takiguchi M
    Microbes Infect; 2013 Nov; 15(13):874-86. PubMed ID: 23968885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inter-clade cross-reactivity of HIV-1-specific T cell responses in human immunodeficiency virus type 1 infection in China.
    Zhao S; Zhai S; Zhuang Y; Wang S; Huang D; Kang W; Li X; Yu XG; Walker BD; Altfeld MA; Sun Y
    Curr HIV Res; 2007 Mar; 5(2):251-9. PubMed ID: 17346138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CTL response to HIV type 1 subtype C is poorly predicted by known epitope motifs.
    Ngandu NG; Bredell H; Gray CM; Williamson C; Seoighe C;
    AIDS Res Hum Retroviruses; 2007 Aug; 23(8):1033-41. PubMed ID: 17725421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-clade cytotoxic T cell response to human immunodeficiency virus type 1 proteins among HLA disparate North Americans and Thais.
    Lynch JA; deSouza M; Robb MD; Markowitz L; Nitayaphan S; Sapan CV; Mann DL; Birx DL; Cox JH
    J Infect Dis; 1998 Oct; 178(4):1040-6. PubMed ID: 9806032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD8
    Kim J; De La Cruz J; Lam K; Ng H; Daar ES; Balamurugan A; Yang OO
    Viral Immunol; 2018 Sep; 31(7):525-536. PubMed ID: 30059271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human immunodeficiency virus type 1 specific cytotoxic T lymphocyte responses in Chinese infected with HIV-1 B'/C Recombinant (CRF07_BC).
    Chen J; Hong K; Jia M; Liu H; Zhang Y; Liu S; Zhang X; Zhao H; Peng H; Ma P; Xing H; Ruan Y; Williams KL; Yu XG; Altfeld M; Walker BD; Shao Y
    Retrovirology; 2007 Aug; 4():62. PubMed ID: 17727734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C.
    Novitsky V; Cao H; Rybak N; Gilbert P; McLane MF; Gaolekwe S; Peter T; Thior I; Ndung'u T; Marlink R; Lee TH; Essex M
    J Virol; 2002 Oct; 76(20):10155-68. PubMed ID: 12239290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection.
    Zheng NN; McElrath MJ; Sow PS; Hawes SE; Diallo-Agne H; Stern JE; Li F; Mesher AL; Robinson AD; Gottlieb GS; Huang Y; Kiviat NB
    J Virol; 2007 Sep; 81(17):9061-71. PubMed ID: 17582003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-B57-restricted cytotoxic T-lymphocyte activity in a single infected subject toward two optimal epitopes, one of which is entirely contained within the other.
    Goulder PJ; Tang Y; Pelton SI; Walker BD
    J Virol; 2000 Jun; 74(11):5291-9. PubMed ID: 10799606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective Suppression of HIV-1 Replication by Cytotoxic T Lymphocytes Specific for Pol Epitopes in Conserved Mosaic Vaccine Immunogens.
    Zou C; Murakoshi H; Kuse N; Akahoshi T; Chikata T; Gatanaga H; Oka S; Hanke T; Takiguchi M
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30674626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.
    Malm M; Rollman E; Ustav M; Hinkula J; Krohn K; Wahren B; Blazevic V
    Viral Immunol; 2005; 18(4):678-88. PubMed ID: 16359234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altering effects of antigenic variations in HIV-1 on antiviral effectiveness of HIV-specific CTLs.
    Ueno T; Idegami Y; Motozono C; Oka S; Takiguchi M
    J Immunol; 2007 May; 178(9):5513-23. PubMed ID: 17442933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroon.
    Gupta SB; Mast CT; Wolfe ND; Novitsky V; Dubey SA; Kallas EG; Schechter M; Mbewe B; Vardas E; Pitisuttithum P; Burke D; Freed D; Mogg R; Coplan PM; Condra JH; Long RS; Anderson K; Casimiro DR; Shiver JW; Straus WL
    J Acquir Immune Defic Syndr; 2006 Jun; 42(2):135-9. PubMed ID: 16760794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antiviral efficacy of HIV-specific CD8⁺ T-cells to a conserved epitope is heavily dependent on the infecting HIV-1 isolate.
    Ranasinghe SR; Kramer HB; Wright C; Kessler BM; di Gleria K; Zhang Y; Gillespie GM; Blais ME; Culshaw A; Pichulik T; Simmons A; Rowland-Jones SL; McMichael AJ; Dong T
    PLoS Pathog; 2011 May; 7(5):e1001341. PubMed ID: 21589893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition patterns of HLA-A2-restricted human immunodeficiency virus-1-specific cytotoxic T-lymphocytes in a cohort of HIV-1-infected individuals.
    Schmitt-Haendle M; Bachmann O; Harrer E; Schmidt B; Bäuerle M; Harrer T
    Viral Immunol; 2005; 18(4):627-36. PubMed ID: 16359229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1-specific cytotoxic T lymphocyte (CTL) responses against immunodominant optimal epitopes slow the progression of AIDS in China.
    Zhai S; Zhuang Y; Song Y; Li S; Huang D; Kang W; Li X; Liao Q; Liu Y; Zhao Z; Lu Y; Sun Y
    Curr HIV Res; 2008 Jun; 6(4):335-50. PubMed ID: 18691032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.